2015 Kern Lipid Conference

2015年科恩脂质会议

• 批准号: 8985457
• 负责人: Robert H Eckel
• 金额: $ 1万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8985457
• 关键词: Academia; Adipose tissue; Affect; Alzheimer' s Disease; Animals; Apolipoproteins C; Area; Atherosclerosis; Award; Biology; Biotechnology; Blood; Cardiovascular Diseases; Cholesterol; Cholesterol Esters; Chronic; Clinical; Clinical Research; Collaborations; Colorado; Complex; Coupled; Data; Development; Disease; Doctor of Philosophy; Dyslipidemias; Ensure; Epidemiology; Event; Faculty; Fish Oils; Fostering; Functional disorder; Genetic; Genetic study; Goals; Human; Human Development; Hyperlipidemia; Hypertriglyceridemia; Industry; Inflammation; Intervention; Investigation; Kidney; LDL Cholesterol Lipoproteins; Left; Link; Lipids; Lipoprotein (a); Lipoproteins; Liver; Liver diseases; Low-Density Lipoproteins; Metabolic; Metabolism; Methods; Molecular; New York; Non-Insulin-Dependent Diabetes Mellitus; Pancreatitis; Participant; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Physiology; Play; Postdoctoral Fellow; Proprotein Convertases; Proteins; Recording of previous events; Recurrence; Research; Research Personnel; Residual state; Resort; Risk; Risk Factors; Science; Scientist; Subtilisins; Therapeutic; Therapeutic Uses; Time; Tissues; Triglycerides; Underrepresented Minority; Universities; Whole Organism; Woman; abstracting; atherogenesis; cardiovascular disorder prevention; cardiovascular disorder risk; cardiovascular disorder therapy; career; graduate student; human data; improved; inhibitor/antagonist; insight; interest; kexin; lectures; lipid disorder; lipid metabolism; lipoprotein disorder; lipoprotein lipase; medical schools; meetings; member; microsomal triglyceride transfer protein; non-alcoholic fatty liver; novel; novel strategies; posters; pre-clinical; prevent; professor; programs; public health relevance; symposium; therapeutic target

 DESCRIPTION (provided by applicant): The Kern Lipid Conference, which was first convened in 1985 and continues to be held annually, explores the complex interplay between lipid metabolism and chronic human disorders such as cardiometabolic diseases, dyslipidemia, atherosclerosis, type II diabetes and Alzheimer's disease. The overall goals of the Kern Lipid Conference are to: 1) promote science relating to broad areas of lipid and lipoprotein metabolism; 2) increase understanding of the pathobiology of dyslipidemia; 3) provide an open forum for scientists from both academia and industry to meet and discuss the latest research findings related to lipid metabolism; 4) ensure at least 25% of meeting participants are early career scientists (graduate students, postdoctoral fellows, and Assistant Professors); and 5) to provide a unique meeting format in which 50% of the time is devoted to formal presentations and 50% is for open discussions of the presentations. The 2015 Kern Lipid Conference, entitled "Emerging therapies for cardiovascular diseases: A dialogue between academic and pharmaceutical research" will be held August 3-5, 2015 at the Vail Marriott Mountain Resort in Vail, CO. The Conference will be co-chaired by Robert Eckel, MD, Ira Goldberg, MD, Margrit Schwarz, PhD, and Roger Newton, PhD. Recent clinical studies have highlighted the importance of residual risk for subsequent cardiovascular disease (CVD) in patients receiving statin medications for cholesterol reduction. These data along with recent genetic studies have led to extraordinary interest in further LDL reduction strategies as well as a focus on other CVD risk factors, including elevated levels of blood triglycerides, Lp(a), and lipid-induced tissue inflammation. This highly interactive meeting will foster discussion between academic and industrial scientists. The Kern Conference ill uniquely focus on the biology behind novel therapies for lipid disorders and their current pharmaceutical development. The speakers are internationally recognized experts and employ a variety of experimental approaches ranging from molecular investigations of basic mechanisms to studies of animal physiology and human clinical interventions. The program will emphasize in-depth discussions of the presentations, which will provide an opportunity to stimulate new insights and initiate new collaborations to further the investigation of the physiology and pathophysiology associated with dyslipidemia and CVD risk. In addition, it should stimulate new ideas to further the development of novel therapies. Also, and importantly, the meeting continues to provide a scientific platform that encourages the participation of early career scientists, enabling them to discuss research in depth with more established investigators.

 描述（由适用提供）：Kern脂质会议于1985年首次召集，并每年继续举行，探讨了脂质代谢和慢性人类疾病之间的复杂相互作用，例如心脏局部疾病，失常疾病，失常，动脉粥样硬化，动脉粥样硬化，II型糖尿病和Alzheimer病。克恩脂质会议的总体目标是：1）促进与脂质和脂蛋白代谢广泛领域有关的科学； 2）越来越了解血脂异常的病理学； 3）为学术界和行业的科学家提供一个开放论坛，以见面并讨论与脂质代谢有关的最新研究结果； 4）确保至少有25％的会议参与者是早期的职业科学家（研究生，博士后研究员和助理教授）； 5）提供独特的会议格式，其中有50％的时间专门用于正式演示，而50％的时间用于公开讨论演示文稿。 2015年的克恩·脂质会议题为“心血管疾病的新兴疗法：学术和制药研究之间的对话”将于2015年8月3日至5日在韦尔市的韦尔万豪山区度假村举行。该会议将由罗伯特·埃克尔（M.D.最近的临床研究强调了随后患心血管疾病（CVD）的残留风险在接受他汀类药物降低胆固醇的患者中的重要性。这些数据以及最近的遗传研究导致对进一步的LDL降低策略以及关注其他CVD危险因素的关注，包括升高的血液甘油三酸酯，LP（A）和脂质诱导的组织注射水平。这次高度互动的会议将促进学术和工业科学家之间的讨论。克恩会议独特地专注于脂质疾病及其目前的药物开发的新型疗法背后的生物学。演讲者是国际公认的专家，采用了各种实验方法，包括基本机制的分子研究到动物生理学和人类临床干预措施的研究。该计划将强调演讲的深入讨论，该讨论将提供一个机会，以刺激新见解并启动新的合作，以进一步与血脂异常和CVD风险相关的生理学和病理生理学的投资。此外，它应该刺激新的想法，以进一步发展新型疗法。同样，重要的是，会议继续提供一个科学平台，鼓励早期职业科学家的参与，使他们能够与更知名的研究人员深入讨论研究。